BillionToOne CTO David Tsao Sells 20,000 Shares and Exercises Options at $2.8

BillionToOne Chief Technology Officer and director David Tsao sold 20,000 Class A common shares on November 2, 2026, a transaction valued at $2.18 million, The future of trading reported. Tsao also exercised options for 20,000 Class A shares at $2.8 per share.

Tsao's Share Sale and Option Exercise

Tsao is a co-founder of BillionToOne, a Menlo Park-based precision diagnostics company founded in 2016 that sells non-invasive prenatal tests under the UNITY brand and oncology liquid biopsies under the Northstar brand from a single blood draw. The company's tests reach OB/GYNs, maternal-fetal medicine specialists and oncologists in the United States and Japan.

The filing covers two steps: the sale of 20,000 Class A common shares and the exercise of options for the same number of shares at $2.8 per share. After both transactions, Tsao directly held 1,000 Class A common shares and 516,667 stock options.

BillionToOne published the original content behind the brief via EDGAR, the U.S. Securities and Exchange Commission's filing system, on November 4, 2026.

BillionToOne's Revenue and Funding Record

BillionToOne reported full-year 2025 revenue of $305.1 million, up from $152.6 million in 2024, according to akta.pro company records. Fourth-quarter 2025 revenue of $96.1 million represented 113% year-over-year growth. The company raised its full-year 2026 revenue guidance to $450-460 million, representing 48-52% growth versus 2025, after earlier 2026 guidance of $415-430 million.

The same records list eight funding rounds, including a $130 million Series D in June 2024 led by Premji Invest and a $125 million Series C in March 2022 led by Adams Street Partners. Total funding stands at $425.9 million.

Earlier BillionToOne Product and Partnership Moves

In May 2026, BillionToOne launched Unity Confirm, a non-invasive circulating fetal cell-based confirmation test using its Fetal Cell Capture technology, which showed 100% concordance with invasive diagnostics across 16 samples in clinical validation, according to the company records.

In April 2026, BillionToOne signed an in-network agreement with UnitedHealthcare effective April 1, 2026, expanding patient access to its tests and improving test pricing for UnitedHealthcare-insured patients. In January 2026, the company integrated UNITY Complete, Northstar Select and Northstar Response into Epic's Aura diagnostics suite under an agreement signed in December 2025, enabling in-EHR test ordering and results delivery into MyChart.

What Comes Next for BillionToOne

BillionToOne has guided full-year 2026 revenue to $450-460 million, representing 48-52% growth versus 2025. The company's Unity Confirm test, launched in May 2026, is available following clinical validation across 16 samples.